BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/23/2015 11:10:00 AM | Browse: 966 | Download: 2079
 |
Received |
|
2015-05-27 20:41 |
 |
Peer-Review Started |
|
2015-05-30 11:49 |
 |
To Make the First Decision |
|
2015-06-18 15:11 |
 |
Return for Revision |
|
2015-06-25 16:47 |
 |
Revised |
|
2015-07-22 16:59 |
 |
Second Decision |
|
2015-09-02 10:32 |
 |
Accepted by Journal Editor-in-Chief |
|
|
 |
Accepted by Executive Editor-in-Chief |
|
2015-09-16 18:40 |
 |
Articles in Press |
|
2015-09-16 18:40 |
 |
Publication Fee Transferred |
|
|
 |
Edit the Manuscript by Language Editor |
|
|
 |
Typeset the Manuscript |
|
2015-11-03 07:25 |
 |
Publish the Manuscript Online |
|
2015-11-23 10:19 |
ISSN |
1949-8454 (online) |
Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
Copyright |
© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved. |
Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
Website |
http://www.wjgnet.com |
Category |
Oncology |
Manuscript Type |
Basic Study |
Article Title |
JAK3 inhibitor Ⅵ is a mutant specific inhibitor for epidermal growth factor receptor with the gatekeeper mutation T790M
|
Manuscript Source |
Invited Manuscript |
All Author List |
Naoyuki Nishiya, Yasumitsu Sakamoto, Yusuke Oku, Takamasa Nonaka and Yoshimasa Uehara |
Funding Agency and Grant Number |
|
Corresponding Author |
Naoyuki Nishiya, PhD, Department of Microbial Chemical Biology and Drug Discovery, Iwate Medical University School of Pharmacy, 2-1-1 Nishitokuta, Yahaba-cho, Shiwa-gun, Iwate 028-3694, Japan. nnishiya@iwate-med.ac.jp |
Key Words |
Epidermal growth factor receptor; Tyrosine kinase inhibitor; Gatekeeper mutation; Non-small cell lung cancers |
Core Tip |
Non-small cell lung cancers caused by mutations in the epidermal growth factor receptor (EGFR) initially respond to tyrosine kinase inhibitors (TKIs). However, the therapeutic efficacy of EGFR-TKIs is limited by drug-resistant mutations such as the gatekeeper mutation T790M. Our present study rediscovered JAK3 inhibitor Ⅵ, a known TKI for Janus kinases (JAKs), as a selective EGFR T790M inhibitor. Our structural analysis revealed similarities among EGFR T790M and JAKs, offering a possible strategy to search for EGFR T790M inhibitors from known kinase inhibitors. Repositioning of the existing therapeutics may facilitate solving clinical problems such as drug resistance and toxicity. |
Publish Date |
2015-11-23 10:19 |
Citation |
Nishiya N, Sakamoto Y, Oku Y, Nonaka T, Uehara Y. JAK3 inhibitor Ⅵ is a mutant specific inhibitor for epidermal growth factor receptor with the gatekeeper mutation T790M. World J Biol Chem 2015; 6(4): 409-418 |
URL |
http://www.wjgnet.com/1949-8454/full/v6/i4/409.htm |
DOI |
http://dx.doi.org/10.4331/wjbc.v6.i4.409 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345